O-1 SEROPREVALENCE AND MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B AND C VIRUSES AMONG PREGNANT WOMEN IN A MATERNAL AND CHILDREN HOSPITAL FROM THE PROVINCE OF BUENOS AIRES

IF 3.7 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Annals of hepatology Pub Date : 2024-02-01 DOI:10.1016/j.aohep.2023.101251
Rosana Solis , Mabel Mora , María Julieta Venturini , Fernando Battiston , Guadalupe Masci , Adrián Zapata , Laura Abojer , Martina Ribeky , Mariana Turturicci , Laura Figueras , Margarita Barris , Alejandra Gaiano , Valeria Silenzi , Andrea Conesa , Gloria Capellini , Mayra Moyano , MANUEL MENDIZABAL
{"title":"O-1 SEROPREVALENCE AND MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B AND C VIRUSES AMONG PREGNANT WOMEN IN A MATERNAL AND CHILDREN HOSPITAL FROM THE PROVINCE OF BUENOS AIRES","authors":"Rosana Solis ,&nbsp;Mabel Mora ,&nbsp;María Julieta Venturini ,&nbsp;Fernando Battiston ,&nbsp;Guadalupe Masci ,&nbsp;Adrián Zapata ,&nbsp;Laura Abojer ,&nbsp;Martina Ribeky ,&nbsp;Mariana Turturicci ,&nbsp;Laura Figueras ,&nbsp;Margarita Barris ,&nbsp;Alejandra Gaiano ,&nbsp;Valeria Silenzi ,&nbsp;Andrea Conesa ,&nbsp;Gloria Capellini ,&nbsp;Mayra Moyano ,&nbsp;MANUEL MENDIZABAL","doi":"10.1016/j.aohep.2023.101251","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>The WHO proposed to eliminate viral hepatitis by the year 2030. To achieve this ambitious goal, we must evaluate the seroprevalence of these infections in different populations. This study aimed to estimate the seroprevalence of hepatitis B (HBV) and C (HCV) among pregnant women and mother-to-child transmission in a maternal hospital.</p></div><div><h3>Materials and Methods</h3><p>We conducted an observational, prospective and consecutive study including pregnant women from San Isidro Maternal and Children Hospital whose births occurred between 05/01/2019 and 04/30/2021. In all patients HBsAg and anti-HCV were assessed during the 1st and 3rd trimester of pregnancy together with HIV. In the case of presenting HBsAg+, anti-HBcIgG was performed on the same sample followed by HBV-DNA PCR. In the case of presenting anti-HCV+, a confirmatory test was performed with PCR HCV-RNA. Neonates of HBsAg+ or HCV+ were follow-up for 3 years.</p></div><div><h3>Results</h3><p>2762 births were included during the period under study. Five (0.18%) HBsAg+ pregnant women were identified, median age was 25 years (range 17-36), of which only 1 had anti-HBcIgG+. Given the suspicion of chronic HBV and the delay in obtaining the HBV-DNA results, treatment with tenofovir was started. In successive controls, no chronic HBV infection was diagnosed in neonates. Anti-HCV+ was detected in 8 (0.29%) patients, with a median age of 29 years (range 19-38 years), of which only one patient presented detectable HCV-RNA, genotype 4. This patient had a diagnosis of HCV chronic prior to pregnancy and her son presented anti-HCV- at age 3. Finally, one patient with HBsAg+ and another with anti-HCV+, but negative viral loads presented HIV+.</p></div><div><h3>Conclusions</h3><p>The gestation period is an excellent opportunity to carry out health checks. During the studied period, the seroprevalence of HBsAg+ and anti-HCV+ was very low. These types of interventions are essential to achieve the objectives set by the WHO.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 ","pages":"Article 101251"},"PeriodicalIF":3.7000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S166526812300354X/pdfft?md5=54771d08a9df93dc710c1e0abc495df4&pid=1-s2.0-S166526812300354X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S166526812300354X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and Objectives

The WHO proposed to eliminate viral hepatitis by the year 2030. To achieve this ambitious goal, we must evaluate the seroprevalence of these infections in different populations. This study aimed to estimate the seroprevalence of hepatitis B (HBV) and C (HCV) among pregnant women and mother-to-child transmission in a maternal hospital.

Materials and Methods

We conducted an observational, prospective and consecutive study including pregnant women from San Isidro Maternal and Children Hospital whose births occurred between 05/01/2019 and 04/30/2021. In all patients HBsAg and anti-HCV were assessed during the 1st and 3rd trimester of pregnancy together with HIV. In the case of presenting HBsAg+, anti-HBcIgG was performed on the same sample followed by HBV-DNA PCR. In the case of presenting anti-HCV+, a confirmatory test was performed with PCR HCV-RNA. Neonates of HBsAg+ or HCV+ were follow-up for 3 years.

Results

2762 births were included during the period under study. Five (0.18%) HBsAg+ pregnant women were identified, median age was 25 years (range 17-36), of which only 1 had anti-HBcIgG+. Given the suspicion of chronic HBV and the delay in obtaining the HBV-DNA results, treatment with tenofovir was started. In successive controls, no chronic HBV infection was diagnosed in neonates. Anti-HCV+ was detected in 8 (0.29%) patients, with a median age of 29 years (range 19-38 years), of which only one patient presented detectable HCV-RNA, genotype 4. This patient had a diagnosis of HCV chronic prior to pregnancy and her son presented anti-HCV- at age 3. Finally, one patient with HBsAg+ and another with anti-HCV+, but negative viral loads presented HIV+.

Conclusions

The gestation period is an excellent opportunity to carry out health checks. During the studied period, the seroprevalence of HBsAg+ and anti-HCV+ was very low. These types of interventions are essential to achieve the objectives set by the WHO.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
O-1 布宜诺斯艾利斯省一家妇幼医院的孕妇乙型肝炎和丙型肝炎血清流行率及母婴传播情况
引言和目标世界卫生组织提出到 2030 年消除病毒性肝炎。为了实现这一宏伟目标,我们必须评估这些感染在不同人群中的血清流行率。本研究旨在估算一家妇产医院中孕妇的乙型肝炎(HBV)和丙型肝炎(HCV)血清流行率以及母婴传播情况。材料和方法我们开展了一项观察性、前瞻性和连续性研究,研究对象包括圣伊西德罗妇幼医院的孕妇,其分娩时间为 2019 年 1 月 5 日至 2021 年 1 月 4 日。所有患者均在妊娠期第一和第三季度接受了 HBsAg 和抗-HCV 以及 HIV 评估。如果出现 HBsAg+,则对同一样本进行抗 HBcIgG 检测,然后进行 HBV-DNA PCR 检测。如果出现抗-HCV+,则进行 PCR HCV-RNA 确认试验。对 HBsAg+ 或 HCV+ 的新生儿进行了为期 3 年的随访。发现 5 名(0.18%)HBsAg+ 孕妇,年龄中位数为 25 岁(17-36 岁),其中只有 1 名孕妇抗 HBcIgG+。鉴于怀疑存在慢性 HBV,且 HBV-DNA 检测结果迟迟未出,因此开始使用替诺福韦进行治疗。在连续的对照组中,没有新生儿被确诊为慢性 HBV 感染。8名患者(0.29%)检测出抗-HCV+,中位年龄为29岁(19-38岁),其中只有一名患者检测出HCV-RNA,基因型为4。这名患者在怀孕前被诊断出患有慢性 HCV,她的儿子在 3 岁时出现了抗 HCV-。最后,一名患者 HBsAg+,另一名患者抗 HCV+,但病毒载量阴性,HIV+。在研究期间,HBsAg+ 和抗-HCV+ 的血清阳性率非常低。这些类型的干预对于实现世界卫生组织设定的目标至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Annals of hepatology
Annals of hepatology 医学-胃肠肝病学
CiteScore
7.90
自引率
2.60%
发文量
183
审稿时长
4-8 weeks
期刊介绍: Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.
期刊最新文献
Editorial board Global multi-societies endorsement of the MAFLD definition An Acknowledgement Biological aging accelerates hepatic fibrosis: Insights from the NHANES 2017-2020 and genome-wide association study analysis. Development of a biodegradable prosthesis through tissue engineering, for the organ-replacement or substitution of the extrahepatic bile duct
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1